| Parameter |
SBP group
n=14 |
non SBP group
n=22 |
P value |
| Age（years） |
50.29 ± 7.03 |
52.82 ± 10.97 |
0.05 |
| Sex |
|
|
|
| male |
13 |
18.00000 |
|
| female |
1 |
4.00000 |
|
| Blood/serum |
|
|
|
| DNA(IU/ml) |
88074.14 ± 176261.26 |
3310201 ± 8332760.094 |
0.17 |
| ALT(U/L) |
59.29 ± 39.48 |
103.95 ± 136.93 |
0.04 |
| AST(U/L) |
124.143 ± 104.30 |
118.09 ± 148.31 |
0.91 |
| TB(umol/L) |
420.77 ± 249.56 |
197.39 ± 209.69 |
0.64 |
| PTA(%) |
31.64 ± 11.58 |
53.41 ± 26.25 |
0.02 |
| INR |
2.52 ± 0.92 |
1.80 ± 0.63 |
0.02 |
| AFP(ng/ml) |
20.78 ± 43.29 |
606.29 ± 2582.24 |
0.39 |
| WBC（10E9/L） |
9.04 ± 5.40 |
4.51 ± 1.97 |
<0.01 |
| N（%） |
71.46 ± 11.37 |
59.68 ± 12.57 |
<0.01 |
| HGB（g/L） |
89.29 ± 10.37 |
101.55 ± 17.87 |
0.10 |
| PLT（10E9/L） |
110.57 ± 72.70 |
91.45 ± 54.48 |
0.64 |
| Ascitic fluid |
|
|
|
| WBC（10E6/L） |
6153.07 ± 20726.75 |
107.73 ± 68.46 |
<0.01 |
| N(%) |
44.36 ± 27.76 |
24.38 ± 18.71 |
<0.01 |
| RBC（10E6/L） |
19719.14 ± 51828.80 |
2615.95 ± 7630.10 |
0.68 |
| GL(mmol/L) |
7.43 ± 3.6 |
8.05 ± 1.93 |
0.24 |
| TP(g/L) |
18.19 ± 11.66 |
12.38 ± 9.40 |
0.23 |
| LDH（U/L） |
392.29 ± 1092.09 |
54.91 ± 26.55 |
0.01 |
| Aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin (TB), prothrombin activity (PTA), international normalized ratio (INR), α-fetoprotein (AFP), platelet count (PLT), hemoglobin (HGB), white blood cells (WBC), percentage of neutrophilic granulocyte (N), red blood cells (RBC)，glucose levels (GL)，total protein (TP), Lactate dehydrogenase (LDH) and Serum HBV DNA (DNA) were measured by a quantitative polymerase chain reaction assay (DaAn Diagnostics assay and Roche Amplicor, limit of detectability of 100 IU/mL; Roche Diagnostics, Basel, Switzerland) after admission. |
|
